实用心电学杂志2024，Vol.33Issue(3)：225-231,7.DOI:10.13308/j.issn.2095-9354.2024.03.002
转甲状腺素蛋白心脏淀粉样变的诊断与治疗研究进展
Research advances in diagnosis and treatment of transthyretin cardiac amyloidosis
摘要
Abstract
Transthyretin cardiac amyloidosis(ATTR-CA)has been considered as a rare cardiac dysfunction with occult onset,rapid progression and high mortality,caused by the accumulation of transthyretin fibrils in the myocardium.Recently,with the development of diagnostic techniques,its detection rate has been increasing.The continuous emergence of various small molecule drugs has also changed the previous situation of lacking therapeutic agents,and its mortality has been reduced.This paper mainly summarizes the latest advances in the diagnosis and treatment of ATTR-CA in recent years.关键词
淀粉样变/心肌病/转甲状腺素/转甲状腺素蛋白心脏淀粉样变/心脏磁共振/小分子药物Key words
amyloidosis/cardiomyopathy/transthyretin/transthyretin cardiac amyloidosis/cardiac magnetic resonance/small molecule drug分类
医药卫生引用本文复制引用
汪月,张俊峰..转甲状腺素蛋白心脏淀粉样变的诊断与治疗研究进展[J].实用心电学杂志,2024,33(3):225-231,7.基金项目
九院临床研究助力计划资助项目(JYLJ202014) （JYLJ202014）
